0001209191-21-021375.txt : 20210317
0001209191-21-021375.hdr.sgml : 20210317
20210317164326
ACCESSION NUMBER: 0001209191-21-021375
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210315
FILED AS OF DATE: 20210317
DATE AS OF CHANGE: 20210317
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hearne Michael S
CENTRAL INDEX KEY: 0001759910
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36282
FILM NUMBER: 21751102
MAIL ADDRESS:
STREET 1: 4747 EXECUTIVE DRIVE
STREET 2: SUITE 210
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LA JOLLA PHARMACEUTICAL CO
CENTRAL INDEX KEY: 0000920465
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 330361285
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4747 EXECUTIVE DRIVE, SUITE 240
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-207-4264
MAIL ADDRESS:
STREET 1: 4747 EXECUTIVE DRIVE, SUITE 240
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-03-15
0
0000920465
LA JOLLA PHARMACEUTICAL CO
LJPC
0001759910
Hearne Michael S
C/O LA JOLLA PHARMACEUTICAL COMPANY
4747 EXECUTIVE DRIVE, SUITE 240
SAN DIEGO
CA
92121
0
1
0
0
Chief Financial Officer
Common Stock
2021-03-15
4
A
0
127
4.8535
A
3490
D
Common Stock
9405490
I
By LP
Employee Stock Option (Right to Buy)
5.71
2021-03-15
4
A
0
127
0.00
A
2031-03-15
Common Stock
127
127
D
These shares were acquired on 3/15/2021 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Tang Capital Management, LLC ("TCM") is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as the Chief Financial Officer of TCM. Mr. Hearne has a pecuniary interest in a portion of the shares beneficially held by TCP.
The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years.
/s/ Michael Hearne
2021-03-17